Israel's BiondVax To Take 'More Global View' With NASDAQ-Only Listing
BiondVax's CEO tells Scrip why the Israel-based vaccine maker wants to delist there and only have a US-based NASDAQ listing and re-make its executive board in to one that's more internationally experienced.
You may also be interested in...
Presenting Phase IIb data on FLU-v, specialized CRO hVIVO now hopes to secure a big pharma partner for Phase III studies and commercialization of the universal flu vaccine candidate. The product has been developed in a joint venture with SEEK.
Vaccitech's potential universal flu vaccine based on prime-boost technology is in early clinical trials in the UK, with partners likely to be sought for later-stage clinical studies; the company has just raised £20m in a Series A round from private investors that included Google's VC arm, GV, and Sequoia China.
The UK's VirionHealth has taken £13m on board in a Series A to develop a novel approach to the treatment of influenza virus infections.